Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhPSMA-7.3 PET/CT in High-Risk Prostate Cancer
NCT05799248Phase 3Recruiting
- Sponsor
- MidLantic Urology
- Start
- Apr 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fludeoxyglucose f 18 in prostate cancer (PCa), sponsored by MidLantic Urology. Started Apr 2023; status: recruiting.
02
Drugs
fludeoxyglucose f 18
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05799248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05799248.